Cadila Healthcare has received approval from USFDA to market Zonisamide capsules of 25 mg, 50 mg and 100 mg. The drug falls in the anti-epileptic segment.According to a release issue by Cadila to the BSE today, the company will market the drug through its US subsidiary Zydus Pharmaceuticals (USA).
